yingweiwo

Mirtazapine (Org3770; 6-Azamianserin)

Alias: ORG-3770; Mirtazapine; Org3770; Org 3770; Remeron; Avanza; Axit; 85650-52-8; Remeron; 61337-67-5; Zispin; 6-Azamianserin; Mepirzepine; Remergil; Mirtazon; Zispin
Cat No.:V1018 Purity: ≥98%
Mirtazapine (formerly Org3770, Org 3770; trade names Remeron, Avanza, Axit, Mirtazon, Zispin),an approved atypical antidepressant drug, is an adrenergic and serotonin receptor antagonist used for treating depression.
Mirtazapine (Org3770; 6-Azamianserin)
Mirtazapine (Org3770; 6-Azamianserin) Chemical Structure CAS No.: 85650-52-8
Product category: 5-HT Receptor
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
25mg
50mg
100mg
250mg
500mg
1g
Other Sizes

Other Forms of Mirtazapine (Org3770; 6-Azamianserin):

  • Esmirtazapine
  • (R)-Mirtazapine
  • (R)-Mirtazapine D3
  • Mirtazapine D3
  • Mirtazapine-d4
  • Mirtazapine
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Mirtazapine (formerly Org3770, Org 3770; trade names Remeron, Avanza, Axit, Mirtazon, Zispin), an approved atypical antidepressant drug, is an adrenergic and serotonin receptor antagonist used for treating depression.

Biological Activity I Assay Protocols (From Reference)
Targets
α2-adrenergic receptor ( pKi = 6.95 ); 5-HT3 Receptor ( pKi = 8.1 ); 5-HT2 Receptor ( pKi = 8.05 ); H1 Receptor ( pKi = 9.3 )
ln Vitro

In vitro activity: Mirtazapine can block 5-HT2 and 5-HT3 receptors and antagonize adrenergic α2-autoreceptors and α2-heteroreceptors. Mirtazapine increases 5-HT1A-mediated serotonergic transmission and norepinephrine release[1]. The primary metabolic enzymes of mirtazapine are cytochrome (CYP) P450 isoenzymes CYP1A2, CYP2D6, and CYP3A4[1]. In vitro, human CD14+ monocytes' activation-induced release of cytokine/chemokine mediators is significantly reduced by mirtazapine (10 μM)[3].

ln Vivo
Mirtazapine (1-20 mg/kg; intraperitoneal injection; once; C57BL/6 mice) treatment dramatically and dose-dependently prevents liver damage caused by Con A[3].
Mirtazapine treatment inhibits the activation of hepatic macrophages and monocytes, reduces the production of pro-inflammatory cytokines (e.g., TNFα) and chemokines (e.g., CXCL1 and CXCL2) by hepatic macrophages and monocytes, and suppresses the increases in hepatic expression of the neutrophil relevant endothelial cell adhesion molecule ICAM-1 induced by Con A. These actions lead to a significant reduction in the recruitment of neutrophils into the liver[3].
Enzyme Assay
The neurochemical and autonomic pharmacological profile of 1,2,3,4,10, 14b-hexahydro-2-methyl-pyrazino[2,1-a]pyrido[2,3-c]pyrido[2, 3-c] [2] benzazepine [+/-)Org 3770) and the related antidepressant drug, mianserin, have been compared. The uptake of [3H]noradrenaline ([3H]NA) in vitro was weakly affected by (+/-)Org 3770 (pKi = 5.6) in contrast to mianserin (pKi = 7.4). Both (+/-)Org 3770 and mianserin facilitated the release of [3H]NA in slices of cortex. The effects of NA mediated by alpha 2-adrenoceptors on the release of both [3H]NA or [3H]serotonin ([3H]5-HT) were antagonized by (+)Org 3770 with pKi values of 8.4 and 8.1, respectively. However, (-)Org 3770 only antagonized the effect of NA on the release of [3H]5-HT (pA2 = 7.7). The binding of [3H]rauwolscine to alpha 2-adrenoceptors was inhibited by (+/-)Org 3770 and mianserin with identical affinity (pKi = 7.0), whereas the binding of [3H]prazosin to alpha 1-adrenoceptors was less potently affected by (+/-)Org 3770 (pKi = 6.4) than by mianserin (pKi = 7.1). A similar difference was found for alpha 1- and alpha 2-adrenoceptors in vas deferens of the rat. The binding of [3H]mianserin to 5-HT2 receptors was less potently blocked by (+/-)Org 3770 (pKi = 8.1) than by mianserin (pKi = 9.4) while the binding of [3H]mepyramine to histamine-1 receptors was more potently affected by (+/-)Org 3770 (pKi = 9.3) than by mianserin (pKi = 8.75). The binding of [3H]quinuclidinylbenzilate to muscarinic cholinergic receptors was blocked equally by (+/-)Org 3770 (pKi = 6.1) and mianserin (pKi = 6.3). Similar data on tryptamine-D, histamine-1 and muscarinic cholinergic receptors in isolated organs were obtained. A prominent role for the blockade of alpha 2-adrenoceptors in the therapeutic effects of mianserin and (+/-)Org 3770 in depression is suggested, probably excluding a role of inhibition of the uptake of NA[2].
Cell Assay
Mirtazapine Effects on Cytokine/Chemokine Production by Human Monocytes and CD4 T Cells in vitro[3]
CD14+ monocytes were isolated from healthy donor peripheral blood using an autoMACS Separator and autoMACS CD14+ positive selection kit. CD14+ cells were seeded into 24-well tissue culture plates (density of 1 × 106 cells/well) in 500 μl RPMI 1,640 medium supplemented with 10% FBS, 1 mM sodium pyruvate, 2 mM L-glutamine, and 100 units/ml penicillin and streptomycin, and non-essential amino acids (NEAA). After 4 h incubation (5% CO2, 37°C) non-adherent cells were removed by washing, and 500 μl of pre-warmed complete fresh media added to wells. Designated wells were treated with mirtazapine (10 μM) or vehicle (0.2 μl/ml DMSO). One hour later Con A (5 μg/ml) or vehicle were added to designated wells, and cells cultured for another 24 h. Supernatants were collected and stored at −80°C until assayed for cytokine/chemokine levels (expressed as pg/ml).
CD4+ T cells were isolated from healthy donor peripheral blood using EasySep™ Human CD4+ T cell isolation kit. Purity of isolated cells as tested by flow cytometry was >97%. Cells were cultured in a 24-well plate (density 106 cells/well) in 500 μl RPMI 1,640 medium supplemented with 10% FBS, 1 mM sodium pyruvate, 2 mM L-glutamine, and 100 units/ml penicillin and streptomycin, and non-essential amino acids (NEAA). Designated wells were treated with mirtazapine (10 μM) or vehicle (0.2 μl/ml DMSO). One hour later Con A (5 μg/ml) or vehicle were added to designated wells, and cells cultured for another 24 h. Supernatants were collected and stored at −80°C until assayed for cytokine levels. Human IL-10, IL-4, and IFNγ were measured in culture supernatants using a human MILLIPLEX kit according to the manufacturer's protocol. The multiplexing analysis was performed using the Luminex 100 system
Animal Protocol
Male C57BL/6 mice (8-10 week old) treated with concanavalin A (Con A)
1 mg/kg, 10 mg/kg, and 20 mg/kg
Intraperitoneal injection; once
Mirtazapine Treatment and Con A Hepatitis Severity[3]
To delineate the impact of mirtazapine treatment in Con A hepatitis, mice were treated 1 h prior to Con A treatment with mirtazapine 1–20 mg/kg intraperitoneally (ip). Blood and liver samples were collected under isoflurane anesthesia 16 h post-Con A treatment (unless otherwise noted) to assess liver injury biochemically (plasma alanine aminotransferase [ALT] activity; measured using Roche-Hitachi Modular-P800 apparatus) and histologically using formalin-fixed liver tissue slices stained with Hematoxylin and Eosin (H&E). Extent of liver parenchymal necrosis was quantitated as previously described using Image J software and an Olympus XC10 camera (acquired using the Olympus VS-ASW software package; original magnification x400). In additional experiments, mirtazapine (20 mg/kg ip) was administered 2 h after Con A treatment (i.e., therapeutically) and mice sacrificed 16 h later and severity of liver injury determined by ALT measurement. In further experiments, the impact of specifically blocking individual receptors known to be impacted by mirtazapine treatment (i.e., 5HT2a, 5HT2c, 5HT3, and H1; also 5HT1a receptor) on the severity of Con A hepatitis was determined by ALT measurement.
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
The absorption of this drug is rapid and complete. Due to first pass metabolism in the liver and metabolism in the gut wall, absolute bioavailability is about 50%. Peak blood concentrations are attained within about 2 hours after an oral dose. Food has little effect on the absorption of mirtazapine, and no dose adjustment is required if it is taken with food. Steady-state levels are achieved by about 5 days after the initial dose. Mirtazapine pharmacokinetics vary across gender and age range. Females and the elderly population have been shown to have higher blood concentrations in comparison to males and younger adults.
This drug is mainly excreted by the kidney. It is 75% eliminated in the urine and 15% eliminated in the feces.
The volume of distribution after an oral steady-state dose was measured to be 107 ± 42L in a pharmacokinetic study.
Total body clearance in males was found to be 31 L/h in a clinical pharmacokinetics study after intravenous administration. **Clearance in elderly patients*
Mirtazapine clearance is slower in the elderly than in younger subjects. Exercise caution when this drug is given to elderly patients. In a clinical trial, elderly males showed a marked decrease in mirtazapine clearance when compared to young males taking the same dose. This difference was less significant when clearance was compared between elderly females and younger females taking mirtazapine. **Clearance in hepatic and renal impairment** Patients with hepatic and renal impairment have decreased rates of clearance and dosage adjustments may be necessary for these patients. Moderate renal impairment and hepatic impairment cause about a 30% decrease in mirtazapine clearance. Severe renal impairment leads to a 50% decrease in mirtazapine clearance.
Metabolism / Metabolites
Mirtazapine is heavily metabolized in humans. Demethylation and hydroxylation and subsequent glucuronide conjugation are the major pathways by which mirtazapine is metabolized. Data from in vitro studies on human liver microsomes show that cytochrome 2D6 and 1A2 lead to the formation of the _8-hydroxy metabolite_ of mirtazapine. The CYP3A enzyme metabolizes this drug into its _N-desmethyl and N-oxide_ metabolites. There are various other unconjugated metabolites of this drug that are pharmacologically active, but are measured in the blood at limited concentrations.
Mirtazapine has known human metabolites that include Mirtazapine N-oxide, N-Desmethylmirtazapine, and 8-hydroxy-mirtazapine.
Mirtazapine is extensively metabolized by demethylation and hydroxylation followed by glucuronide conjugation. Cytochrome P450 2D6 and cytochrome P450 1A2 are involved in formation of the 8-hydroxy metabolite of mirtazapine, and cytochrome P450 3A4 is responsible for the formation of the N-desmethyl and N-oxide metabolites. Several metabolites possess pharmacological activity, but plasma levels are very low.
Route of Elimination: This drug is known to be substantially excreted by the kidney (75%).
Half Life: 20-40 hours
Biological Half-Life
20-40 hours
Toxicity/Toxicokinetics
Toxicity Summary
Mirtazapine acts as an antagonist at central pre-synaptic alpha(2)-receptors, inhibiting negative feedback to the presynaptic nerve and causing an increase in NE release. Blockade of heteroreceptors, alpha(2)-receptors contained in serotenergic neurons, enhances the release of 5-HT, increasing the interactions between 5-HT and 5-HT1 receptors and contributing to the anxiolytic effects of mirtazapine. Mirtazapine also acts as a weak antagonist at 5-HT1 receptors and as a potent antagonist at 5-HT2 (particularly subtypes 2A and 2C) and 5-HT3 receptors. Blockade of these receptors may explain the lower incidence of adverse effects such as anxiety, insomnia, and nausea. Mirtazapine also exhibits significant antagonism at H1-receptors, resulting in sedation. Mirtazapine has no effects on the reuptake of either NE or 5-HT and has only minimal activity at dopaminergic and muscarinic receptors.
Toxicity Data
LD50: 600-720mg/kg (oral, mice) (L1855)
LD50: 320-490mg/kg (oral, rat) (L1855)
References

[1]. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. Fall 2001;7(3):249-64.

[2]. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408.

[3]. The Antidepressant Mirtazapine Inhibits Hepatic Innate Immune Networks to Attenuate Immune-Mediated Liver Injury in Mice. Front Immunol. 2019 Apr 12;10:803.

Additional Infomation
Pharmacodynamics
**General effects and a note on suicidality** Mirtazapine is effective in treating moderate to severe depression and treats many symptoms normally associated with this condition. These symptoms may include disturbed sleep, lack of appetite, and anhedonia, in addition to anxiety.. It is important to note that suicidal ideation and behavior may emerge or increase during treatment with mirtazapine, as with any other antidepressant. This risk is especially pronounced in younger individuals. Patients, medical professionals, and families should monitor for suicidal thoughts, worsening depression, anxiety, agitation, sleep changes, irritable behavior, aggression, impulsivity, restlessness, and other unusual behavior when this drug is taken or the dose is adjusted. Do not administer mirtazapine to children. When deciding to prescribe this drug, carefully consider the increased risk of suicidal thoughts and behavior, especially in young adults. **Effects on appetite and weight gain** In addition to the above effects, mirtazapine exerts stimulating effects on appetite, and has been used for increasing appetite and decreasing nausea in cancer patients. Some studies and case reports have shown that this drug improves eating habits and weight gain in patients suffering from anorexia nervosa when administered in conjunction with psychotherapy and/or other psychotropic drugs. In a clinical trial, women with depression experienced a clinically significant mean increase in body weight, fat mass, and concentrations of leptin when treated with mirtazapine for a 6-week period, with a lack of effect on glucose homeostasis. **Effects on sleep** The use of mirtazapine to treat disordered sleep has been leveraged from its tendency to cause somnolence, which is a frequently experienced adverse effect by patients taking this drug. Mirtazapine has been shown to exert beneficial effects on sleep latency, duration, and quality due to its sedating properties. Insomnia is a common occurrence in patients with depression, and mirtazapine has been found to be efficacious in treating this condition.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C17H19N3
Molecular Weight
265.35
Exact Mass
265.157
Elemental Analysis
C, 76.95; H, 7.22; N, 15.84
CAS #
85650-52-8
Related CAS #
(S)-Mirtazapine; 61337-87-9; (S)-Mirtazapine-d3; (R)-Mirtazapine; 61364-37-2; Mirtazapine-d3; 1216678-68-0; Mirtazapine-d4; 1215898-55-7; (R)-Mirtazapine-d3; 85650-52-8; 61337-67-5 (deleted); 1448014-35-4 (HCl); 207516-99-2 (HCl); 207516-99-2 (2HCl); 868363-97-7 (HBr); 868528-74-9 (HBr); 341512-89-8 (hemihydrate)
PubChem CID
4205
Appearance
White to off-white solid powder
Density
1.2±0.1 g/cm3
Boiling Point
432.4±45.0 °C at 760 mmHg
Melting Point
114-116ºC
Flash Point
215.3±28.7 °C
Vapour Pressure
0.0±1.0 mmHg at 25°C
Index of Refraction
1.668
LogP
2.75
Hydrogen Bond Donor Count
0
Hydrogen Bond Acceptor Count
3
Rotatable Bond Count
0
Heavy Atom Count
20
Complexity
345
Defined Atom Stereocenter Count
0
SMILES
N1C2N3C(C4C(CC=2C=CC=1)=CC=CC=4)CN(C)CC3
InChi Key
RONZAEMNMFQXRA-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3
Chemical Name
5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene
Synonyms
ORG-3770; Mirtazapine; Org3770; Org 3770; Remeron; Avanza; Axit; 85650-52-8; Remeron; 61337-67-5; Zispin; 6-Azamianserin; Mepirzepine; Remergil; Mirtazon; Zispin
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: 50~53 mg/mL (188.4~199.7 mM)
Water: <1 mg/mL
Ethanol: ~53 mg/mL (~199.7 mM)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.42 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.5 mg/mL (9.42 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: ≥ 2.5 mg/mL (9.42 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.


 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 3.7686 mL 18.8430 mL 37.6861 mL
5 mM 0.7537 mL 3.7686 mL 7.5372 mL
10 mM 0.3769 mL 1.8843 mL 3.7686 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP)
CTID: NCT05452174
Phase: Phase 1/Phase 2    Status: Withdrawn
Date: 2024-11-19
Novel Pilot Study to Treat Symptoms of IBS with Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator
CTID: NCT06684470
PhaseEarly Phase 1    Status: Not yet recruiting
Date: 2024-11-12
Prophylactic Mirtazapine and Different Doses of Intrathecal Morphine in Preventing Nausea and Vomiting After Cesarean Section
CTID: NCT06681805
Phase: N/A    Status: Completed
Date: 2024-11-08
Mirtazapine Versus Dexamethasone in Preventing Postoperative Nausea and Vomiting
CTID: NCT04547842
PhaseEarly Phase 1    Status: Completed
Date: 2024-10-08
Mirtazapine and Methamphetamine Drug-drug Interaction Study
CTID: NCT04614584
Phase: Phase 1    Status: Completed
Date: 2024-09-27
View More

Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients with Advanced Stage Cancer
CTID: NCT05170919
Phase: Phase 2    Status: Enrolling by invitation
Date: 2024-09-19


Trial of Mirtazapine for Depression in IBD
CTID: NCT06309472
Phase: Phase 2    Status: Recruiting
Date: 2024-08-22
Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment
CTID: NCT06323837
Phase: Phase 2    Status: Recruiting
Date: 2024-08-13
Evaluating the Effect of Mirtazapine on Anxiety in Parkinson's Disease Patients
CTID: NCT06530290
Phase: Phase 2    Status: Recruiting
Date: 2024-07-31
Mirtazapine for Acute and Chronic Post Mastectomy Pain
CTID: NCT06499090
PhaseEarly Phase 1    Status: Not yet recruiting
Date: 2024-07-16
Mirtazapine Versus Placebo in Functional Dyspepsia
CTID: NCT01240096
Phase: Phase 4    Status: Completed
Date: 2024-07-01
Effects of Mirtazapine on Appetite in Advanced Cancer Patients
CTID: NCT00488072
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-05-16
Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ
CTID: NCT03935685
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-05-14
Efficacy of Mirtazapine in Major Depressive Disorder With Insomnia
CTID: NCT05978219
Phase: Phase 4    Status: Completed
Date: 2024-04-02
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
CTID: NCT02893371
Phase:    Status: Terminated
Date: 2024-03-12
Mirtazapine vs Sumatriptan in the Treatment of Postdural Puncture Headache
CTID: NCT05108688
Phase: Phase 4    Status: Completed
Date: 2024-01-22
Elucidating Mechanisms That Underlie the Symptomatology of Functional Dyspepsia Using Novel Techniques and Its Therapeutic Validation Using Neuromodulators
CTID: NCT06213948
Phase: Phase 1    Status: Recruiting
Date: 2024-01-19
Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.
CTID: NCT03283488
Phase: Phase 2    Status: Completed
Date: 2023-07-07
Mirtazapine in Cancer-related Poly-symptomatology
CTID: NCT04763135
Phase: Phase 3    Status: Terminated
Date: 2023-06-08
Improving Sleep After TKA Using Mirtazapine and Quetiapine
CTID: NCT04728581
Phase: N/A    Status: Not yet recruiting
Date: 2023-06-02
Effect of Mirtazapine Versus Placebo in Patients With Non-small Cell Lung Cancer and Anorexia
CTID: NCT04748523
Phase: N/A    Status: Completed
Date: 2023-04-27
Validating the Effect og Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum
CTID: NCT03785691
Phase: Phase 2    Status: Terminated
Date: 2023-01-30
Nutrition and Pharmacological Algorithm for Oncology Patients Study
CTID: NCT04155008
Phase: Phase 4    Status: Terminated
Date: 2022-11-16
Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea
CTID: NCT04446039
Phase:    Status: Co
A Phase IV double blind multi-site, individually randomised parallel group controlled trial investigating the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in patients in primary care who are taking long term maintenance antidepressants but now feel well enough to consider stopping medication.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2016-11-22
BETTER-B (Feasibility)
CTID: null
Phase: Phase 4    Status: Completed
Date: 2016-02-16
The effect of mirtazapine (REMERGON®) on gastric motility and satiation in healthy subjects
CTID: null
Phase: Phase 4    Status: Completed
Date: 2015-02-16
Functional MRI (fMRI) after challenge and treatment with antidepressants and their relation to the clinical course, to the Hypothalamus-Hypophysis-Adrenocortical Axis and the colon microbiome
CTID: null
Phase: Phase 4    Status: Completed
Date: 2014-09-25
Patient stratification and treatment response prediction in neuropharmacotherapy using PET/MR –
CTID: null
Phase: Phase 4    Status: Completed
Date: 2014-06-17
Establish limits for fitness to drive with prolonged use of ICADTS class III medication
CTID: null
Phase: Phase 4    Status: Completed
Date: 2014-05-28
The effect of low doses of mirtazapine and quetiapine on sleep and daytime functioning.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2014-03-03
A pilot study to treat emotional disorders in Primary Care with evidence-based psychological techniques: A randomized controlled trial
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2013-12-26
Mirtazapine added to SSRIs for treatment resistant depression in primary care: a placebo controlled randomised controlled trial
CTID: null
Phase: Phase 4    Status: Completed
Date: 2013-06-19
The effect of various medications on emotioal processing, attention, experiences and sensory information processing
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2013-02-15
Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders
CTID: null
Phase: Phase 4    Status: Completed
Date: 2011-10-27
OCTUMI-4: Evaluation of Mirtazapine and Folic Acid for Schizophrenia:
CTID: null
Phase: Phase 4    Status: Prematurely Ended, Completed
Date: 2010-08-17
Depressions-Spektrums-Störung und differenzielle Effekte neuerer Antidepressiva auf die Verkehrssicherheit
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2010-07-14
Antidepressive response to add-on occupational therapy in patients with major depression: A randomized controlled multicentre trial
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2010-03-18
“TERAPIA ELECTROCONVULSIVA DE CONSOLIDACIÓN ASOCIADA A PSICOFÁRMACOS VERSUS FARMACOTERAPIA EN LA PREVENCIÓN DE RECIDIVAS EN EL TRASTORNO DEPRESIVO MAYOR. UN ENSAYO CLÍNICO, PRAGMÁTICO, PROSPECTIVO ALEATORIZADO”.
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2009-02-04
A prospective, single-blinded (rater-blinded), randomized, parallel group study of the efficacy of Quetiapine XR in the treatment of patients with Acute Stress Disorder (DSM-VI 308.3)
CTID: null
Phase: Phase 3    Status: Completed
Date: 2008-08-18
Evaluation de l'action neuroréparatrice fonctionnelle et morphologique du traitement antidepresseur au cours de la rémission clinique dans la dépression recurrente.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2008-07-04
mirtazapine versus placebo in functional dyspepsia: a randomized, double-blind, placebo-controlled trial
CTID: null
Phase: Phase 4    Status: Completed
Date: 2006-08-02
Hippocampal volume in young adults with moderate to severe depression before and after combined antidepressant therapy
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2005-08-18
Hur påverkar Remeron alkoholkonsumtionen? How will Remeron influence alcohol consumption in high consumers?
CTID: null
Phase: Phase 2    Status: Completed
Date: 2004-09-06
Investigation of biological and clinical predictor of antidepressant response for personalized medicine in depression ; a randomized controlled trial
CTID: UMIN000006417
Phase:    Status: Complete: follow-up complete
Date: 2011-09-27
Efficacy and safety of mirtazapine in patients with depression and insomnia
CTID: UMIN000005944
PhaseNot applicable    Status: Pending
Date: 2011-08-01
The investigation of treatment for major depression compared monotherapy of mirtazapine, sertraline or duloxetine with combination therapy of mirtazapine and sertraline, or mirtazapine and duloxetine
CTID: UMIN000004567
PhaseNot applicable    Status: Complete: follow-up complete
Date: 2011-04-01
Efficacy of mirtazapine for sleep disturbance and anxiety symptoms compared with selective serotonin reuptake inhibitors in patients with major depressive disorder: a multicenter open-label randomized controlled trial.
CTID: UMIN000004144
PhaseNot applicable    Status: Complete: follow-up complete
Date: 2010-09-02
None
CTID: jRCT2080221141
Phase:    Status:
Date: 2010-06-29
Premedication with mirtazapine reduces postoperative nausea and vomiting.
CTID: UMIN000003822
Phase:    Status: Complete: follow-up complete
Date: 2010-06-25

Biological Data
  • Mirtazapine
    The effect of mirtazapine on Lin-7C, CASK, and CTNNB1 mRNA expression levels.Sci Rep. 2014; 4: 5433.
  • Mirtazapine
    qRT-PCR analysis of Lin-7C gene expression in hSCC cell lines.Sci Rep. 2014; 4: 5433.


    Mirtazapine
    Quantitative analysis of spontaneous metastasis using different human tumor cells.Sci Rep. 2014; 4: 5433.
  • Mirtazapine
    Comparison of cellular proliferation in the control group (without mirtazapine) and the mirtazapine-treated groups.Sci Rep. 2014; 4: 5433.


    Mirtazapine
    The functional effect of mirtazapine for antimetastatic potential in human metastatic cancer cells.Sci Rep. 2014; 4: 5433.
Contact Us